Role of MAP kinase in tumor progression and invasion
Tóm tắt
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway is a frequent event in tumorigenesis. MAPKs have been implicated in cell migration, proteinase-induction, regulation of apoptosis, and angiogenesis, events that are essential for successful completion of metastasis. In this review, we discuss the potential role that MAPKs play in metastasis by regulating cell migration, proteinase-induction and apoptosis.
Tài liệu tham khảo
Reddy KB, Krueger JS, Kondapaka SB, Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 82: 268–273. 1999
Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209–4218. 2001
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822, 1999
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478–1483, 1997
Salh B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D, Pelech S: Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19: 731–740, 1999
Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384–388, 2000
Wilsbacher JL, Goldsmith EJ, Cobb MH: Phosphorylation of MAP kinases by MAP/ERK involves multiple regions of MAP kinases. J Biol Chem 274: 16988–16994, 1999
Ahn NG: The MAP kinase cascade. Discovery of a new signal transduction pathway. Mol Cell Biochem 127–128: 201–209, 1993
Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogenactivated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143–180, 1999
Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11: 211–218, 1999
Lenormand P, Brondello JM, Brunet A, Pouyssegur J: Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins. J Cell Biol 142: 625–633, 1998
Adachi M, Fukuda M, Nishida E: Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148: 849–856, 2000
Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM: Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. Embo J 15: 3621–3632, 1996
Chernoff J: Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J Cell Physiol 180: 173–181, 1999
Zheng CF, Guan KL: Dephosphorylation and inactivation of the mitogen-activated protein kinase by a mitogeninduced Thr/Tyr protein phosphatase. J Biol Chem 268: 16116–16119, 1993
Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K: The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271: 6497–6501, 1996
Gonzalez FA, Raden DL, Rigby MR, Davis RJ: Heterogeneous expression of four MAP kinase isoforms in human tissues. FEBS Lett 304: 170–178, 1992
Cheng M, Boulton TG, Cobb MH: ERK3 is a constitutively nuclear protein kinase. J Biol Chem 271: 8951–8958, 1996
Zhou G, Bao ZQ, Dixon JE: Components of a new human protein kinase signal transduction pathway. J Biol Chem 270: 12665–12669, 1995
Lee JD, Ulevitch RJ, Han J: Primary structure of BMK1: A new mammalian mapkinase. Biochem Biophys Res Commun 213: 715–724, 1995
Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998
English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH: Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 274: 31588–31592, 1999
Abe MK, Kuo WL, Hershenson MB, Rosner MR: Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, and cell growth. Mol Cell Biol 19: 1301–1312, 1999
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153–183, 2001
Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075–2080, 1997
Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ: MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 281: 1668–1671, 1998
Elion EA: Routing MAP kinase cascades. Science 281: 1625–1626, 1998
Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ: A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277: 693–696, 1997
Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ: A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281: 1671–1674, 1998
Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ: Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372: 798–800, 1994
Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121–125, 1990
Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14: 455–463, 1992
Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev 9: 321–331, 1990
Coutts AS, Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071–4074, 1998
McCawley LJ, Li S, Wattenberg EV, Hudson LG: Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274: 4347–4353, 1999
Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747–1753, 2002
Overall CM, Lopez-Otin C: Strategies for mmp inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657–672, 2002
Ree AH, Bjornland K, Brunner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin ExpMetastasis 16: 205–215, 1998
Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271: 10672–10680, 1996
Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70: 722–726, 1997
Brogley MA, Cruz M, Cheung HS: Basic calcium phosphate crystal induction of collagenase 1 and stromelysin expression is dependent on a p42/44 mitogen-activated protein kinase signal transduction pathway. J Cell Physiol 180: 215–224, 1999
Mazumdar A, Adam L, Boyd D, Kumar R: Heregulin regulation of urokinase plasminogen activator and its receptor: Human breast epithelial cell invasion. Cancer Res 61: 400–405, 2001
Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066–8074, 2001
Vu TH, Werb Z: Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14: 2123–2133, 2000
Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163–176, 2000
Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415–433, 2000
Sehgal I, Baley PA, Thompson TC: Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56: 3359–3365, 1996
Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 53: 2208–2211, 1993
Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189: 161–168, 1999
Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T: Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58: 582–586, 1994
Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL: Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 53: 5802–5807, 1993
Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59: 1252–1258, 1999
Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47: 1523–1528, 1987
Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087–2091, 1993
Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463–516, 2001
Yeow KM, Phillips BW, Beaudry PP, Leco KJ, Murphy G, Edwards DR: Expression of MMPs and TIMPs in mammalian cells. Methods Mol Biol 151: 181–189, 2001
Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174, 2002
Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated molecular process. Cell 84: 359–369, 1996
Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB: Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 75: 205–209, 1998
Zeigler ME, Chi Y, Schmidt T, Varani J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 180: 271–284, 1999
Hartmann G, Weidner KM, Schwarz H, Birchmeier W: The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem 269: 21936–21939, 1994
Klemke RL, Yebra M, Bayna EM, Cheresh DA: Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol 127: 859–866, 1994
Howe AK, Juliano RL: Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade. J Biol Chem 273: 27268–27274, 1998
Tan JL, Ravid S, Spudich JA: Control of nonmuscle myosins by phosphorylation. Annu Rev Biochem 61: 721–759, 1992
Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137: 481–492, 1997
Ridley AJ: Rho GTPases and cell migration. J Cell Sci 114: 2713–2722, 2001
Chrzanowska-Wodnicka M, Burridge K: Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133: 1403–1415, 1996
Kaibuchi K, Kuroda S, Amano M: Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68: 459–486, 1999
Amano M, Fukata Y, Kaibuchi K: Regulation and functions of Rho-associated kinase. ExpCell Res 261: 44–51, 2000
Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F: Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol 150: 797–806, 2000
Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M: Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 277: 28256–28264, 2002
Collins P, Webb C: Estrogen hits the surface. Nat Med 5: 1130–1131, 1999
Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/p21ras/ MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J 15: 1292–1300, 1996
Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16: 116–127, 2002
Bi R, Broutman G, Foy MR, Thompson RF, Baudry M: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 97: 3602–3607, 2000
Rambo CO, Szego CM: Estrogen action at endometrial membranes: alterations in luminal surface detectable within seconds. J Cell Biol 97: 679–685, 1983
Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239–256, 2002
Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 30-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475–5478, 1999
Reddy KB, Keshamouni VG, Chen YQ: The level of tyrosine kinase activity regulates the expression of p21/ WAF1 in cancer cells. Int J Oncol 15: 301–306, 1999
Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402–411, 1996
Gulli LF, Palmer KC, Chen YQ, Reddy KB: Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7: 173–178, 1996
Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456–1462, 1995
Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD: programd cell death and the control of cell survival: lessons from the nervous system. Science 262: 695–700, 1993
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATPdependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489, 1997
Ashkenazi A: Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2: 420–430, 2002
Eastman A: Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 6: 45–52, 1995
Stadheim TA, Xiao H, Eastman A: Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 61: 1533–1540, 2001
Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484–16490, 2001
Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC, Krammer PH, Eriksson JE: MAPK/ERK signaling in activated T cells inhibits CD95/ Fas-mediated apoptosis downstream of DISC assembly. Embo J 19: 5418–5428, 2000
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331, 1995
Greene LA: Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium. J Cell Biol 78: 747–755, 1978
Buckley S, Driscoll B, Barsky L, Weinberg K, Anderson K, Warburton D: ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Am J Physiol 277: L159–166, 1999
Erhardt P, Schremser EJ, Cooper GM: B-Raf inhibits programd cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308–5315, 1999
Anderson CN, Tolkovsky AM: A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. J Neurosci 19: 664–673, 1999
Sarker M, Ruiz-Ruiz C, Robledo G, Lopez-Rivas A: Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 21: 4323–4327, 2002
Scheid MP, Duronio V: Dissociation of cytokine-induced phosphorylation of bad and activation of PKB/akt: involvement of MEK upstream of bad phosphorylation. Proc Natl Acad Sci USA 95: 7439–7444, 1998
Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285–291, 1995
Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ: Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 182: 821–828, 1995
Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3–3 not BCL-X(L). Cell 87: 619–628, 1996